Singapore markets closed

  • Straits Times Index

    3,217.41
    +10.42 (+0.32%)
     

  • Nikkei

    31,857.62
    -14.90 (-0.05%)
     

  • Hang Seng

    17,809.66
    +436.63 (+2.51%)
     

  • FTSE 100

    7,608.08
    +6.23 (+0.08%)
     

  • Bitcoin USD

    26,913.48
    -174.09 (-0.64%)
     

  • CMC Crypto 200

    579.66
    +0.90 (+0.15%)
     

  • S&P 500

    4,288.05
    -11.65 (-0.27%)
     

  • Dow

    33,507.50
    -158.84 (-0.47%)
     

  • Nasdaq

    13,219.32
    +18.05 (+0.14%)
     

  • Gold

    1,864.60
    -14.00 (-0.75%)
     

  • Crude Oil

    90.77
    -0.94 (-1.02%)
     

  • 10-Yr Bond

    4.5730
    -0.0240 (-0.52%)
     

  • FTSE Bursa Malaysia

    1,424.17
    -15.94 (-1.11%)
     

  • Jakarta Composite Index

    6,939.89
    +2.06 (+0.03%)
     

  • PSE Index

    6,321.24
    -64.28 (-1.01%)
     

Better Long-Term Buy: AbbVie or Novo Nordisk?

Jim Halley, The Motley Fool
·5-min read
Better Long-Term Buy: AbbVie or Novo Nordisk?

Pharmaceutical companies Novo Nordisk (NYSE: NVO) and AbbVie (NYSE: ABBV) seem to be headed in separate directions. Denmark-based Novo Nordisk, thanks to growing sales of diabetes drug Ozempic and obesity therapy Wegovy, is predicting sales to grow between 24% to 30% and operating profit to rise 28% to 34% this year. AbbVie, on the other hand, thanks to the loss of patent protection for immunology blockbuster Humira, has forecasted 2023 adjusted earnings per share (EPS) to drop by 20% to 23%, from 2022 levels.

Continue reading